Dr. Eugene Shkolyar, MD

Dr. Shkolyar practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Shkolyar's NPI, 1851786230, was assigned on April 1, 2015. Dr. Shkolyar graduated from David Geffen School of Medicine at UCLA in 2015. Dr. Shkolyar holds California license A143968.

Dr. Shkolyar's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Shkolyar's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Shkolyar is also affiliated with Stanford Health Care Tri-Valley. The medical group on file is The Permanente Medical Group, Inc. Dmand AI also links Dr. Shkolyar to 2 more hospitals and 2 medical groups, each named with a free account. Dr. Shkolyar's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shkolyar practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Shkolyar's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Shkolyar is board certified in urology by the American Board of Urology. Dr. Shkolyar is licensed in California.

Dmand AI lists urinary endoscopy among the conditions Dr. Shkolyar treats.

CMS data shows 552 Medicare services from Dr. Shkolyar across 10 procedure codes in 2024, for 310 Medicare patients. Medicare paid $73,104 for them.

CMS counts 310 Medicare patients who saw Dr. Shkolyar in 2024. The largest group is 65 to 74, with 150 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Shkolyar's median patient age at 68, with 19% women.

In 2024, Dr. Shkolyar wrote 63 Medicare Part D claims for 37 patients. 95% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $139 in total drug cost. In 2021, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Shkolyar for performance year 2024, reported as part of a group. Dr. Shkolyar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shkolyar as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 24 papers to Dr. Shkolyar, published from 2017 to 2025. 2020 was the busiest year, with 6. The most frequent topics are Urinary Bladder Neoplasms, Cystoscopy and Artificial Intelligence. Dr. Shkolyar has published most often in Urol Oncol. Dr. Shkolyar's most frequent co-authors are Joseph Chihping Liao, MD, Timothy Chan Chang, MD and John Thomas Leppert, MD.

CMS Open Payments shows 26 general payments to Dr. Shkolyar from 12 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 80% of the total. Ethicon Inc. paid the most, $8,924.

Dmand AI lists 1 award for Dr. Shkolyar, most recently Urology Care Foundation Research Scholar in 2023.

Dr. Shkolyar graduated from David Geffen School of Medicine at UCLA in 2015.

Dr. Shkolyar is in network with 8 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.